Hall Laurie J Trustee lowered its stake in shares of Novartis AG (NYSE:NVS – Free Report) by 1.2% in the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 27,215 shares of the company’s stock after selling 337 shares during the period. Hall Laurie J Trustee’s holdings in Novartis were worth $2,648,000 as of its most recent filing with the SEC.
Other institutional investors have also added to or reduced their stakes in the company. Fisher Asset Management LLC raised its holdings in Novartis by 15.7% in the 3rd quarter. Fisher Asset Management LLC now owns 1,706,009 shares of the company’s stock valued at $196,225,000 after acquiring an additional 231,851 shares in the last quarter. FMR LLC raised its stake in shares of Novartis by 5.5% in the third quarter. FMR LLC now owns 1,353,412 shares of the company’s stock valued at $155,669,000 after purchasing an additional 70,314 shares in the last quarter. Natixis Advisors LLC lifted its position in Novartis by 2.9% in the third quarter. Natixis Advisors LLC now owns 938,844 shares of the company’s stock worth $107,986,000 after purchasing an additional 26,317 shares during the period. Bank of Montreal Can boosted its stake in Novartis by 18.7% during the third quarter. Bank of Montreal Can now owns 780,980 shares of the company’s stock worth $90,289,000 after buying an additional 123,077 shares in the last quarter. Finally, Canada Pension Plan Investment Board bought a new stake in Novartis in the 2nd quarter valued at $64,610,000. 13.12% of the stock is owned by institutional investors and hedge funds.
Analyst Ratings Changes
NVS has been the subject of a number of analyst reports. BMO Capital Markets raised their price objective on shares of Novartis from $118.00 to $120.00 and gave the stock a “market perform” rating in a report on Wednesday, October 30th. HSBC cut shares of Novartis from a “hold” rating to a “reduce” rating in a research note on Wednesday, December 4th. Finally, Erste Group Bank reissued a “hold” rating on shares of Novartis in a report on Tuesday, November 19th. Two equities research analysts have rated the stock with a sell rating and seven have issued a hold rating to the stock. According to MarketBeat, Novartis presently has an average rating of “Hold” and a consensus price target of $121.50.
Novartis Price Performance
NYSE:NVS opened at $97.51 on Monday. The company has a quick ratio of 0.90, a current ratio of 1.11 and a debt-to-equity ratio of 0.55. The firm has a market cap of $199.30 billion, a PE ratio of 11.32, a price-to-earnings-growth ratio of 1.36 and a beta of 0.57. Novartis AG has a 12 month low of $92.35 and a 12 month high of $120.92. The company’s 50-day moving average price is $100.61 and its two-hundred day moving average price is $109.01.
Novartis (NYSE:NVS – Get Free Report) last announced its earnings results on Tuesday, October 29th. The company reported $2.06 EPS for the quarter, topping the consensus estimate of $1.94 by $0.12. Novartis had a return on equity of 34.80% and a net margin of 35.96%. The business had revenue of $12.82 billion for the quarter, compared to the consensus estimate of $12.62 billion. During the same period in the previous year, the business earned $1.74 EPS. On average, equities analysts anticipate that Novartis AG will post 7.63 EPS for the current fiscal year.
About Novartis
Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.
Featured Articles
- Five stocks we like better than Novartis
- How to Calculate Options Profits
- Earn High Dividends With 2 Top REITs Set to Perform in 2025
- Canada Bond Market Holiday: How to Invest and Trade
- Oilfield Leader SLB: An AI Name You Need to Know
- What Are Dividend Contenders? Investing in Dividend Contenders
- Top ETFs That Beat the Market in 2024 and Could Do It Again
Want to see what other hedge funds are holding NVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novartis AG (NYSE:NVS – Free Report).
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.